Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
significant difference among age, gender, smoking status and histologic type
between patients with and without MET amplification. MET amplification
was more frequent in advanced stage and solid predominant subtype of
adenocarcinoma. MET protein expression was performed in 395 patients
and 138 were positive. Patients with MET protein expression positive had an
inferior overall survival compared to those without MET protein expression
(45.0 months vs 65.8 months; P=0.001) . Multivariate analysis revealed that
MET expression was independent prognostic factor for poor overall survival
(HR=1.497,P=0.017),while,the MET amplification shows weak relevance for
overall survival (HR=1.974,P=0.251). Conclusion: MET amplification was rare in
Chinese NSCLC without EGFR mutation, with a prevalence of about 1%. MET
expression but not amplification could be an independent prognostic factor
for shorter OS among those EGFR wild-type NSCLC patients .
Keywords: non-small cell lung cancer, MET, amplification, Overexpression
POSTER SESSION 2 – P2.03B: ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/
IMMUNOTHERAPY
BIOMARKERS –
TUESDAY, DECEMBER 6, 2016
P2.03B-079 DECREASED EXPRESSION OF MIR-125A-3P IS
ASSOCIATED WITH THE CLINICAL OUTCOME OF NON-SMALL CELL
LUNG CANCER PATIENTS
Chunyan Wu 1 , Likun Hou 2
1 Shanghai Pulmonary Hospital Affiliated To Tongji University, Shanghai/China,
2 Department of Pathology Shanghai Pulmonary Hospital, Tongji University School
of Medicine, Shanghai/China
Background: The microRNA miR-125a-3p is derived from the 3-end of
pre-miR-125a, proved associated with several cancers, such as glioma, gastric
cancer, and prostate cancer. However, there are few studies proved the link
between miR-125a-3p and non-small cell lung cancer (NSCLC). The aim of this
study was to identify the prognostic significance of miR-125a-3p expression
and chemotherapy in NSCLC patients. Methods: The GEO database was
applied to analyze miR-125a-3p expression in NSCLC, and 148 NSCLC samples
and 30 adjacent normal lung tissue specimens were analyzed for the
expression of miR-125a-3p by quantitative RT-PCR. (NSCLC). Results: Our
results showed that the expression of miR-125a-3p in adjacent normal tissues
is higher than that in NSCLC tissues. There were several clinical parameters be
demonstrated associated with miR-125a-3p expression, such as lymph-node
metastasis and tumor diameter. Furthermore, high expression of miR-125a-3p
with chemotherapy prolong the overall survival (OS) and disease free survival
(DFS) relative to untreated patients with low expression of miR-125a-3p.
Conclusion: MiR-125a-3p is a significant prognostic biomarker for
chemotherapy in NSCLC, and it could derive a novel therapeutic strategies to
combat NSCLC.
Keywords: MiR-125a-3p, NSCLC, Prognosis, chemotherapy
POSTER SESSION 2 – P2.03B: ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/
IMMUNOTHERAPY
BIOMARKERS –
TUESDAY, DECEMBER 6, 2016
P2.03B-080 A COMPREHENSIVE TEST OF CANCER TREATMENT-
RELATED GENES FOR THE CLINICAL SAMPLES OF NON-SMALL CELL
LUNG CANCER (NSCLC)
Yoshiaki Inoue 1 , Ato Sugiyama 1 , Kohei Aoki 1 , Hiroki Fukuda 1 , Masatoshi Gika 1 ,
Yotaro Izumi 1 , Kunihiko Kobayashi 2 , Mitsuo Nakayama 1 , Koichi Hagiwara 3
1 Thoracic Surgery, Saitama Medical University Saitama Medical Center, Saitama
Kawagoe/Japan, 2 Respiratory Medicine, Saitame Medical University Saitama
International Medical Center, Saitama Hidaka/Japan, 3 Pulmonary Medicine, Jichi
Medical University, Shimotsuke/Japan
Background: Molecular targeted therapies are one of the key drugs for
NSCLC. For all advanced NCSLC patients to receive precise molecular targeted
therapies, mutation analysis should be comprehensively analyzed from tissue
and/or cytological samples with high sensitivity and cost-effectiveness. To
satisfy these requirements, we established a system called MINtS(Mutation
Investigation System using a Next-generation Sequencer). According to our
basic data, by deep sequencing, MINtS enables us to detect genetic alterations
from the clinical specimens of which cancer cell content is just over 1%. The lists
of mutations are EGFR, KRAS, BRAF, HER2, and ALK/RET/ROS1 fusion genes. We
report the data analyzed from the clinical cytological and tissue samples using
MINtS. Methods: MINtS adapted amplicon sequencing strategy. For the EGFR,
KRAS, BRAF and HER2 genes, the target regions are amplified by the multiplex
PCR. For the ALK, RET and ROS1 fusion genes as well as OAZ1 housekeeping gene
S516 Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017